Skip to main content

BriaCell Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (BCT)

AI-generated - The Globe and Mail - Thu Jul 18, 8:46PM CDT

BriaCell Therapeutics Corp is among the group of bottom performing stocks year-to-date on the Toronto Stock Exchange. This means each stock on this list has seen its share price decrease at a faster rate than the rest of the market so far this year.

This report is generated monthly. It highlights the 25 companies with the greatest percentage decrease in share price year-to-date. Stocks in this category are generally sold to preserve capital or held for speculation.

Companies experiencing dramatic increases in share price can do so for a variety of reasons – including bearish changes in sector outlook, or the company is experiencing financial difficulties generally due to an inability to service its debt.

SymbolNameTotal ReturnPeriod
VGCXVictoria Gold Corp-88.936782YTD
CJR-BCorus Entertainment Inc-84.507042YTD
BCTBriaCell Therapeutics Corp-83.974359YTD
NCUNevada Copper Corp-76.923077YTD
LPENLoop Energy Inc-73.333333YTD
APSAptose Biosciences Inc-73.134328YTD
SOT-UNSlate Office REIT-67.283951YTD
TAIGTaiga Motors Corp-65.730337YTD
CHWChesswood Group Ltd-64.425428YTD
AMMAlmaden Minerals Ltd-62.162162YTD
GFPGreenFirst Forest Products Inc-61.578947YTD
DNDelta 9 Cannabis Inc-60YTD
CRWNCrown Capital Partners Inc-58.405546YTD
SVASernova Corp-57.857143YTD
SMCSulliden Mining Capital Inc-57.142857YTD
EXROExro Technologies Inc-57.03125YTD
NUMINuminus Wellness Inc-54.545455YTD
NPKVerde AgriTech Ltd-54.140127YTD
AVNTAvant Brands Inc-53.571429YTD
LACLithium Americas Corp-51.176471YTD
PMETPatriot Battery Metals Inc-51.158107YTD
VRTSVertiqal Studios Corp-50YTD
WRXWestern Resources Corp-50YTD
SSRMSSR Mining Inc-47.116737YTD
IVQ-UInvesque Inc-46.938776YTD

All data provided as of July 18, 2024.

More about BriaCell Therapeutics Corp

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

BriaCell Therapeutics Corp is listed under BCT on the Toronto Stock Exchange.

Artificial intelligence at Report on Business

Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.